Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Adult patient with chronic or persistent ITP.
Must have failed or are unable to receive standard of care treatments for ITP.
Must have at least two platelet counts < 30,000/µL during the last 2 months prior to screen date.
ITP associated with lymphoma, chronic lymphocytic leukemia, transplant, or thrombocytopenia associated with myeloid dysplasia.
Subject has uncontrolled or poorly controlled hypertension.
Any of the following laboratory abnormalities: neutrophil count of < 1,500/µL, or transaminase levels (ALT, AST) > 1.5x ULN, total bilirubin > 2.0 mg/dL.
Active HBV or HCV infection.
Current or recent enrollment in an investigational drug or device study.